2024 Biopharma Ecosystems 
Frost & Sullivan
MARCH 22, 2024
However, the pharma/biopharma industry shows overall stagnant R&D activity. growth from 2023 to 2024. What is driving transformation in the pharma industry? Small-to-mid and emerging biopharma players contribute over 16%. Are you considering drug discovery ecosystem partnerships to survive and thrive?
Frost & Sullivan
JUNE 24, 2024
The sessions of the American Society of Clinical Oncology ( ASCO ) 2024 conference focused on this year’s theme – The Art and Science of Cancer Care: From comfort to cure. During ASCO 2024, AbbVie unveiled new data from its ADC platform, which is now being used for the development of therapies that specifically target solid tumors.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Frost & Sullivan
MAY 9, 2025
The Expanding Role of Clinical Contract Peripheral Services As the pharmaceutical and biopharma industries recalibrate after the COVID-19 pandemic, clinical trial outsourcing has surged, creating significant opportunities for contract research organizations (CROs). billion in 2024, is projected to grow at a CAGR of 10.7%, reaching $122.13
Frost & Sullivan
MARCH 16, 2025
The global proteomics industry is poised for significant expansion between 2024 and 2030, driven by advances in research and pharmaceutical applications. The Proteomics Ecosystem: Whos Driving Innovation? This blog explores the key factors influencing the industry, the competitive landscape, and emerging growth opportunities.
Frost & Sullivan
JANUARY 23, 2025
The 43rd JP Morgan Healthcare Conference , held from January 1316, 2025, in San Francisco, brought together a vibrant ecosystem of global pharma stakeholders, innovative startups, emerging biotech companies, and investors. South Koreas Investments : Lotte Biologics invested $3.3
Expert insights. Personalized for you.
52 
Let's personalize your content